Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $41.7 million.

  • Stoke Therapeutics' Total Current Liabilities fell 16.32% to $41.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year decrease of 16.32%. This contributed to the annual value of $40.1 million for FY2024, which is 29.97% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Total Current Liabilities stood at $41.7 million, which was up 7.88% from $38.7 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Total Current Liabilities peaked at $49.9 million during Q3 2024, and registered a low of $21.8 million during Q2 2023.
  • Its 3-year average for Total Current Liabilities is $36.8 million, with a median of $38.7 million in 2025.
  • As far as peak fluctuations go, Stoke Therapeutics' Total Current Liabilities dropped by 21.02% in 2023, and later surged by 103.76% in 2024.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Total Current Liabilities stood at $31.4 million in 2022, then decreased by 1.83% to $30.8 million in 2023, then grew by 29.97% to $40.1 million in 2024, then decreased by 16.32% to $41.7 million in 2025.
  • Its Total Current Liabilities stands at $41.7 million for Q3 2025, versus $38.7 million for Q2 2025 and $44.7 million for Q1 2025.